A Unique Approach
to Immunology
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies. Launched in 2015, we have created and advanced multiple product candidates into clinical trials for inflammatory/autoimmune diseases and cancer, formed collaborations with world-class partners, and built a robust development pipeline.
Our scientific platform consists of unique protein engineering strategies, including the directed evolution of immune proteins into novel, multi-targeted therapeutics. With such differentiated candidates, we hope to improve outcomes in patients with severe inflammatory and autoimmune diseases.
Join us in the discovery and development of next-generation immunotherapies.
Current job openingsLearn more about Alpine
Alpine’s Pipeline
We have a diverse pipeline across inflammatory/autoimmune disease and immuno-oncology. For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filings, corporate presentations, and scientific publications.
Acazicolcept (ALPN-101)
Dual CD28/ICOS Costimulation Antagonist
Autoimmune Diseases
Povetacicept (ALPN-303)
Dual BAFF/APRIL B cell cytokine antagonist
Autoimmune Diseases
Alpine Immune Sciences News Releases
- Truveta and Alpine Immune Sciences Announce Strategic Partnership to Access Truveta’s Community to Accelerate Recruitment to Povetacicept Clinical TrialsTruveta’s 28 health system members provide over 16% of patient care in the United States. BELLEVUE and SEATTLE, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Today, Truveta and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced a strategic partnership to help accelerate clinical trial recruitment
- Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific ConferencesSEATTLE --(BUSINESS WIRE)--Mar. 20, 2023-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology &
- Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual MeetingSEATTLE --(BUSINESS WIRE)--Mar. 16, 2023-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster with an oral presentation at the American Academy of
